Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
No aliases recorded.
Cabotegravir/rilpivirine (CAB/RPV), sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.
Read the full article on WikipediaHIV infection Clinical criteria: Treatment Phase: Initial Patient must be antiretroviral treatment naive, AND The treatment must be in combination with other antiretroviral agents.
“Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).”
“tablets: 45 hoursinjection: 13–28 weeks”
Working under the parallel aged-care framework? Aged-care equivalent →